Compass Therapeutics, Inc. (CMPX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.18-1.36%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Cash burn from operations stays near -$17.3M or improves: -60.9M vs -17.3M.
Compass Therapeutics advances with FDA path confirmation after Tovecimig trial win. Phase 1 data for CTX-8371 supports future product potential. The company controls operating losses near -$20.3M and manages cash burn around -$17.3M. These steps could lead to eventual revenue growth from $0 in 2026 to $25M in 2027.
Compass remains loss-making with operating income worsening from -$16.6M to -$20.3M. Analysts expect EPS losses near -$0.43 in 2026 and -$0.46 in 2027. Cash burn is increasing, and revenue is uncertain, risking further declines and failure to reach profitability.
The market prices in high optionality with implied growth over 40% in 5 years but also elevated risk from ongoing losses. Our fair value at $0.39 reflects this balance, while consensus revenue growth is not well defined.
Breaks if: Cash burn worsens beyond -$17.3M next quarter
Breaks if: Operating loss worsens beyond -$20.3M next quarter
Breaks if: No FDA path progress or negative regulatory news by end 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent financial performance, which raises concerns about its ability to execute on its long-term plans.
The market appears to be pricing in a high level of fragility due to the company's expensive valuation compared to peers. However, the current valuation does not fully reflect its weak financial performance and elevated risks.
Management is focused on advancing clinical development and controlling cash burn, but recent results show an increase in operating losses. The near-term risk of missing earnings remains low, but the company operates in a high-miss-rate industry, which adds uncertainty.
The long-term thesis hinges on management's ability to advance clinical trials successfully and maintain sufficient cash to fund operations. Additionally, the performance of sector bellwethers and overall economic conditions will significantly impact CMPX's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings report showed a miss. This miss raises concerns about the company's financial performance. There are no new supportive factors to offset this.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue fails to reach $25M in 2027
In the next 1 to 3 years, CMPX's outlook is clouded by weak fundamentals and elevated risks, despite some positive sector momentum. Not investment advice.